Contact this trialFirst, we need to learn more about you.
Chemotherapy
NRC-2694-A + Paclitaxel for Head and Neck Cancer
Recruiting3 awardsPhase 2
Baltimore, Maryland
This trial tests a new drug, NRC-2694-A, taken with paclitaxel, for patients with head and neck cancer that has come back or spread and did not respond to previous treatments. The new drug aims to block proteins that help cancer grow, while paclitaxel helps kill the cancer cells. Paclitaxel is a well-established drug known for its effectiveness in treating various cancers, including head and neck cancer. This combination could offer a new treatment option for these patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service